Abstract
Fourteen patients with small cell lung cancer (SCLC) previously treated with one or two chemotherapy regimens were entered in this study. 5-Fluorouracil 370 mg/m2 or 300 mg/m2 was given with folinic acid 200 mg/m2 by i.v. rapid infusion on days 1 through 5. Cycles were repeated every 28 days. There were no objective responses. One patient had stable disease for 47 weeks. The overall median survival duration was 23 weeks. Toxicity was comparable to that seen in other studies of 5-fluorouracil plus folinic acid.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase II
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Carcinoma, Small Cell / drug therapy*
-
Carcinoma, Small Cell / mortality
-
Female
-
Fluorouracil / administration & dosage*
-
Fluorouracil / adverse effects
-
Humans
-
Leucovorin / administration & dosage*
-
Leucovorin / adverse effects
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / mortality
-
Male
-
Middle Aged
-
Neoplasm Recurrence, Local / drug therapy*
-
Neoplasm Recurrence, Local / mortality
-
Remission Induction
-
Survival Rate